

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CONCORD HEALTHCARE GROUP CO., LTD.

美中嘉和醫學技術發展集團股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2453)

INSIDE INFORMATION PROFIT ALERT

This announcement is made by Concord Healthcare Group Co., Ltd. (the “**Company**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board (the “**Board**”) of directors (the “**Directors**”) of the Company wishes to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that, based on the preliminary assessment of the unaudited consolidated management accounts of the Group for the six months ended June 30, 2026 (the “**First Half of 2026**”) (prepared in accordance with the IFRS Accounting Standards issued by the International Accounting Standards Board), it is expected that the Group will (i) record a revenue of approximately RMB260 million to RMB280 million for the First Half of 2026, as compared to the revenue of approximately RMB200.9 million for the six months ended June 30, 2025, representing a year-on-year increase of approximately 29% to 39%; and (ii) record a gross profit of approximately RMB63 million to RMB83 million for the First Half of 2026, as compared to the gross profit of approximately RMB0.38 million for the six months ended June 30, 2025, representing a year-on-year increase of approximately 16,349% to 21,571%.

The further year-on-year growth in revenue and the significant increase in gross profit for the First Half of 2026 were mainly attributable to: the increase in revenue from the proton therapy business of Guangzhou Concord Cancer Center Co., Ltd. (廣州泰和腫瘤醫院有限公司) under the Group, with the cumulative total number of patients served exceeding 1,000 and the number of patients treated in single day surpassing 100. Moving forward, the Group will continue to optimize its service processes, improve diagnosis and treatment efficiency, with the aim of delivering high-quality medical services to more oncology patients.

The Board hereby reminds investors that the Company is still finalizing the interim results of the Group for the relevant period. The information contained in this announcement is only a preliminary assessment based on the internal management records of the Company and with reference to the information currently available, which has not been reviewed or confirmed by the auditor or the audit committee of the Company, and may be subject to finalization and necessary adjustments. Due to changes in market conditions during the relevant period, the actual financial results of the Group for the relevant period may differ from the financial results disclosed in this announcement. Pursuant to the Listing Rules, the interim results announcement of the Group for the relevant period is expected to be published by the end of August 2026.

Shareholders and potential investors of the Company are reminded to rationally treat any information not officially published by the Company, and Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Concord Healthcare Group Co., Ltd.
YANG Jianyu
Chairman of the Board and Executive Director

Beijing, the PRC, July 30, 2026

As at the date of this announcement, the Board comprises (i) Dr. YANG Jianyu, and Mr. JIANG Wei as executive Directors; (ii) Mr. WANG Lei, Mr. SONG Qingbao and Mr. SHI Botao as non-executive Directors; (iii) Ms. LI Xuemei, Mr. SUN Yansheng and Mr. NG Kwok Yin as independent non-executive Directors; and (iv) Ms. JIANG Li as employee Director.